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Cyclic adenosine monophosphate (cAMP) and/or cyclic
guanosine monophosphate (cGMP) have been suggested
to play specific roles in processes of memory. These cyc-
lic nucleotides are hydrolyzed by specific enzymes, i.e.
phosphodiesterases (PDEs). Thus, selective PDE inhibi-
tors preventing the breakdown of cAMP and/or cGMP
could improve memory. Studies with different timing of
treatment with specific PDE inhibitors indicated that
distinct underlying signaling pathways for early and late
consolidation processes exist corresponding to specific
time-windows for memory consolidation into long-term
memory. There is evidence that the underlying mechan-
isms of PDE inhibition on the observed behavioral
effects are independent of possible cerebrovascular
effects. Most likely the underlying mechanisms are a
cGMP/PKG pathway for early consolidation processes
and a cAMP/PKA pathway for late consolidation pro-
cesses. In addition, the early-phase cGMP/PKG signaling
actually requires late-phase cAMP/PKA-signaling in
long-term memory formation. Recently, the effects of
specific PDE inhibitors are explored on other cognitive
domains including acquisition processes/short-term
memory and information processing. It will be shown
that elevation of central cGMP levels or cAMP levels
after treatment with a specific PDE inhibitor both
improve acquisition processes/short-term memory. The
effects of specific PDE inhibitors on information proces-
sing by using a sensory gating paradigm indicate that
elevation of cGMP together with cAMP using a specific
PDE inhibitor improves basic information processing,
whereas elevation of cGMP alone has no effect. In a
translational approach we also investigated the effect of
PDE5 inhibition on cognition in humans. However, in
contrast to studies including rodents and monkeys, PDE5
inhibition had no effect on cognition including memory
processes in humans. Yet as sensory gating was also not
affected this could underlie the translational value of this
measure. It is clear that the transition of a drug from pre-
clinical to clinical creates translational hurdles. Within the
context as described above, the latest results of specific
PDE inhibitors on cognitive processes will be presented
and its implications will be discusses for finding and test-
ing new cognition enhancers.
Published: 2 September 2015
doi:10.1186/2050-6511-16-S1-A18
Cite this article as: Prickaerts: Targeting cyclic nucleotides in CNS drug
discovery: a translational approach into cognition enhancement. BMC
Pharmacology and Toxicology 2015 16(Suppl 1):A18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Correspondence: jos.prickaerts@maastrichtuniversity.nl
Department of Psychiatry and Neuropsychology, School for Mental Health
and Neuroscience, Maastricht University, Maastricht, The Netherlands
Prickaerts BMC Pharmacology and Toxicology 2015, 16(Suppl 1):A18
http://www.biomedcentral.com/2050-6511/16/S1/A18
© 2015 Prickaerts This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
